Literature DB >> 28287637

Minimal residual disease (MRD) assessment by flow cytometry after ASCT for AL amyloidosis: are we there yet?

H Lee1, P Duggan1, P Neri1, J Tay1, N J Bahlis1, V H Jimenez-Zepeda1.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28287637     DOI： 10.1038/bmt.2017.28

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  13 in total

Review 1.  Flow cytometry in immunoglobulin light chain amyloidosis: Short review.

Authors:  Jana Filipova; Lucie Rihova; Pavla Vsianska; Zuzana Kufova; Elena Kryukova; Fedor Kryukov; Roman Hajek
Journal:  Leuk Res       Date:  2015-07-13       Impact factor: 3.156

Review 2.  Light-chain (AL) amyloidosis: diagnosis and treatment.

Authors:  Vaishali Sanchorawala
Journal:  Clin J Am Soc Nephrol       Date:  2006-10-11       Impact factor: 8.237

3.  The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis.

Authors:  Bruno Paiva; María-Belén Vídriales; José J Pérez; María-Consuelo López-Berges; Ramón García-Sanz; Enrique M Ocio; Natalia de Las Heras; Rebeca Cuello; Alfonso García de Coca; Emilia Pardal; José Alonso; Magdalena Sierra; Abelardo Bárez; José Hernández; Lissbett Suárez; Josefina Galende; María-Victoria Mateos; Jesús F San Miguel
Journal:  Blood       Date:  2011-01-25       Impact factor: 22.113

Review 4.  New criteria for response assessment: role of minimal residual disease in multiple myeloma.

Authors:  Bruno Paiva; Jacques J M van Dongen; Alberto Orfao
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

5.  The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment.

Authors:  Eli Muchtar; Dragan Jevremovic; Angela Dispenzieri; David Dingli; Francis K Buadi; Martha Q Lacy; Wilson Gonsalves; Suzanne R Hayman; Prashant Kapoor; Nelson Leung; Stephen Russell; John A Lust; Yi Lin; Ronald S Go; Rajshekhar Chakraborty; Steven Zeldenrust; Shaji K Kumar; Robert A Kyle; S Vincent Rajkumar; Morie A Gertz
Journal:  Blood       Date:  2016-10-11       Impact factor: 22.113

Review 6.  Utility of flow cytometry studies in the management of patients with multiple myeloma.

Authors:  Bruno Paiva; Juana Merino; Jesús F San Miguel
Journal:  Curr Opin Oncol       Date:  2016-11       Impact factor: 3.645

7.  High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma.

Authors:  Bruno Paiva; Norma C Gutiérrez; Laura Rosiñol; María-Belén Vídriales; María-Ángeles Montalbán; Joaquín Martínez-López; María-Victoria Mateos; María-Teresa Cibeira; Lourdes Cordón; Albert Oriol; María-José Terol; María-Asunción Echeveste; Raquel de Paz; Felipe de Arriba; Luis Palomera; Javier de la Rubia; Joaquín Díaz-Mediavilla; Anna Sureda; Ana Gorosquieta; Adrian Alegre; Alejandro Martin; Miguel T Hernández; Juan-José Lahuerta; Joan Bladé; Jesús F San Miguel
Journal:  Blood       Date:  2011-11-29       Impact factor: 22.113

8.  Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma.

Authors:  M Cavo; C Terragna; G Martinelli; S Ronconi; E Zamagni; P Tosi; R M Lemoli; M Benni; G Pagliani; G Bandini; S Tura
Journal:  Blood       Date:  2000-07-01       Impact factor: 22.113

9.  New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.

Authors:  Giovanni Palladini; Angela Dispenzieri; Morie A Gertz; Shaji Kumar; Ashutosh Wechalekar; Philip N Hawkins; Stefan Schönland; Ute Hegenbart; Raymond Comenzo; Efstathios Kastritis; Meletios A Dimopoulos; Arnaud Jaccard; Catherine Klersy; Giampaolo Merlini
Journal:  J Clin Oncol       Date:  2012-10-22       Impact factor: 44.544

10.  Levels of minimal residual disease detected by quantitative molecular monitoring herald relapse in patients with multiple myeloma.

Authors:  Roland Fenk; Muharrem Ak; Guido Kobbe; Ulrich Steidl; Carolin Arnold; Mark Korthals; Ali Hünerlitürkoglu; Ulrich-Peter Rohr; Slawomir Kliszewski; Alf Bernhardt; Rainer Haas; Ralf Kronenwett
Journal:  Haematologica       Date:  2004-05       Impact factor: 9.941
View more
  4 in total

1.  Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis.

Authors:  Surbhi Sidana; Eli Muchtar; M Hasib Sidiqi; Dragan Jevremovic; Angela Dispenzieri; Wilson Gonsalves; Francis Buadi; Martha Q Lacy; Suzanne R Hayman; Taxiarchis Kourelis; Prashant Kapoor; Ronald S Go; Rahma Warsame; Nelson Leung; S Vincent Rajkumar; Robert A Kyle; Morie A Gertz; Shaji K Kumar
Journal:  Am J Hematol       Date:  2020-02-14       Impact factor: 10.047

2.  The utility of repeat kidney biopsy in systemic immunoglobulin light chain amyloidosis.

Authors:  Avital Angel-Korman; Aala Jaberi; Vaishali Sanchorawala; Andrea Havasi
Journal:  Amyloid       Date:  2019-10-09       Impact factor: 7.141

3.  Clinical value of minimal residual disease assessed by multiparameter flow cytometry in amyloid light chain amyloidosis.

Authors:  Xiaozhe Li; Beihui Huang; Junru Liu; Meilan Chen; Jingli Gu; Juan Li
Journal:  J Cancer Res Clin Oncol       Date:  2021-05-08       Impact factor: 4.553

4.  Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis.

Authors:  Efstathios Kastritis; Ioannis V Kostopoulos; Evangelos Terpos; Bruno Paiva; Despina Fotiou; Maria Gavriatopoulou; Nikolaos Kanellias; Dimitrios C Ziogas; Maria Roussou; Magdalini Migkou; Evangelos Eleutherakis-Papaiakovou; Ioannis P Trougakos; Ourania Tsitsilonis; Meletios A Dimopoulos
Journal:  Blood Cancer J       Date:  2018-05-24       Impact factor: 11.037
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.